These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 3040306)

  • 21. The effect of ouabain on pressor responses to infused noradrenaline in patients with essential hypertension.
    Nishimura M; Kikuchi K; Aoki K; Nozawa A; Honma C; Kobayakawa H; Yamamoto M; Shimazaki M; Kudoh C; Sakamoto T
    J Hypertens Suppl; 1988 Dec; 6(4):S354-6. PubMed ID: 2853744
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Endogenous marinobufagenin-like immunoreactive factor and Na+, K+ ATPase inhibition during voluntary hypoventilation.
    Bagrov AY; Fedorova OV; Austin-Lane JL; Dmitrieva RI; Anderson DE
    Hypertension; 1995 Nov; 26(5):781-8. PubMed ID: 7591018
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of changes in dietary sodium intake on normotensive subjects with and without a genetic predisposition to essential hypertension.
    Weissberg PL; West MJ; Wilkins MR; Kricka LJ
    J Hypertens Suppl; 1984 Dec; 2(3):S511-3. PubMed ID: 6100752
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A quantitative receptor assay for "digitalis-like" compounds in serum. Demonstration of raised concentrations in essential hypertension and correlation with arterial blood pressure.
    Moreth K; Renner D; Schoner W
    Klin Wochenschr; 1987 Feb; 65(4):179-84. PubMed ID: 3031360
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evidence for increased levels of a circulating ouabainlike factor in essential hypertension.
    Sagnella GA; Jones JC; Shore AC; Markandu ND; MacGregor GA
    Hypertension; 1986 May; 8(5):433-7. PubMed ID: 3699882
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Blood pressure in essential hypertension correlates with the concentration of a circulating inhibitor of the sodium pump.
    Moreth K; Kuske R; Renner D; Schoner W
    Klin Wochenschr; 1986 Mar; 64(5):239-44. PubMed ID: 3009961
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Marinobufagenin, an endogenous alpha-1 sodium pump ligand, in hypertensive Dahl salt-sensitive rats.
    Fedorova OV; Kolodkin NI; Agalakova NI; Lakatta EG; Bagrov AY
    Hypertension; 2001 Feb; 37(2 Pt 2):462-6. PubMed ID: 11230319
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Na-K-ATPase inhibitor dissociated from hypertension-associated plasma protein.
    Weiler EW; Khalil-Manesh F; Gonick HC; Prins BA; Purdy RE; Sensharma DK
    Am J Hypertens; 1999 Apr; 12(4 Pt 1):364-73. PubMed ID: 10232496
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Higher plasma Na+,K+-ATPase inhibitory activity in essential hypertensive patients.
    Vasdev S; Fernandez PG; Longerich L; Gault H
    Can J Cardiol; 1989; 5(5):249-54. PubMed ID: 2547501
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evidence for a Na-K-ATPase-inhibitor in erythrocytes of patients with essential hypertension.
    Walter U; Müller S
    Eur J Clin Invest; 1985 Aug; 15(4):209-14. PubMed ID: 2995050
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Plasma sodium pump inhibitor in essential hypertension and normotensive subjects with hypertensive heredity.
    de Thé H; Devynck MA; Rosenfeld J; Pernollet MG; Elghozi JL; Meyer P
    J Cardiovasc Pharmacol; 1984; 6 Suppl 1():S49-54. PubMed ID: 6204159
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A circulating Na+-K+ATPase inhibitor, erythrocyte sodium transport and hypertension in patients with chronic renal failure.
    Kariya K; Sano H; Yamanishi J; Saito K; Furuta Y; Fukuzaki H
    Clin Exp Hypertens A; 1986; 8(2):167-83. PubMed ID: 2424645
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Predominance of high molecular weight plasma Na(+)-K(+)-ATPase inhibitor in essential hypertension.
    Gonick HC; Weiler EW; Khalil-Manesh F; Weber MA
    Am J Hypertens; 1993 Aug; 6(8):680-7. PubMed ID: 8217031
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Investigation of the endogenous Na+-pump inhibitor in essential hypertension and blood volume expansion.
    Devynck MA; Pernollet MG; Deray G; Wauquier I; Delva P; Rieu M; Henning G; Cloix JF; Crabos M; Baudouin-Legros M
    J Hypertens Suppl; 1984 Dec; 2(3):S453-5. PubMed ID: 6100747
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Digoxin-like immunoreactivity: is it still worth measuring?
    Goto A; Yamada K; Yagi N; Hui C; Sugimoto T
    Life Sci; 1991; 49(23):1667-78. PubMed ID: 1658518
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Endogenous Na+ transport inhibitor in human hypertension: further biochemical and chemical studies.
    Cloix JF; Crabos M; Grichois ML; Guicheney P; Meyer P
    Klin Wochenschr; 1987; 65 Suppl 8():146-53. PubMed ID: 3037183
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sodium-potassium pump inhibitor in the mechanism of one-kidney, one wrap hypertension in dogs.
    Pamnani MB; Swindall BT; Schooley JF; Ghai R; Haddy FJ
    Cell Mol Biol (Noisy-le-grand); 1999 Feb; 45(1):115-21. PubMed ID: 10099845
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Modifications induced by plasma of gestational hypertensive women on the Na+/K+-ATPase obtained from human placenta.
    Cester N; Rabini RA; Tranquilli AL; Lucarelli G; Salvolini E; Staffolani R; Amler E; Zolese G; Mazzanti L
    Mol Cell Biochem; 1997 May; 170(1-2):125-9. PubMed ID: 9144326
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Franz Volhard Lecture 1996. Sodium transport inhibitors and hypertension.
    de Wardener HE
    J Hypertens Suppl; 1996 Dec; 14(5):S9-18. PubMed ID: 9120690
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Digoxin-like immunoreactivity, displacement of ouabain and inhibition of Na+/K+ ATPase by four steroids known to be increased in essential hypertension.
    Seccombe DW; Pudek MR; Nowaczynski W; Humphries KH
    Clin Biochem; 1989 Feb; 22(1):17-21. PubMed ID: 2539926
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.